Press Release

October 29, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra-Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051, Maharashtra. Dalal Street, Mumbai – 400 001, Maharashtra. Symbol: STAR Scrip Code: 532531 Dear Madam/ Sir, Sub: Press Release Please find enclosed herewith Press Release issued by the Company titled: “Strides Delivers Strong Performance with Q2FY27 Revenue at ₹14,297m, Grew 17% YoY Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to ₹2,509m, Crossing ₹2,500m in a Quarter for the First Time” Board Meeting for considering the unaudited financial results for the quarter and half year ended September 30, 2026 commenced at 16:45 hrs (IST) and concluded at 18:15 hrs (IST). The above information shall be made available on the website of the Company at www.strides.com. This is for your information and records. Thanks & Regards, For Strides Pharma Science Limited, Manjula Ramamurthy Company Secretary & Compliance Officer ICSI Membership No.: A30515 Encl. As above Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India |Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com Press Release 29 October 2026 Strides Delivers Strong Performance with Q2FY27 Revenue at ₹14,297m, Grew 17% YoY Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to ₹2,509m, Crossing ₹2,500m in a Quarter for the First Time Q2FY27 Performance Highlights • Revenue up 17.1% YoY to ₹14,297m, led by strong 31% YoY growth in the Ex-US Markets • US business at ₹6,855m ($73m), up 9% YoY; 3 products launched during the quarter • Ex-US Markets revenue at ₹6,963m ($74m), up 31% YoY, surpassing the US business in quarterly revenue for the first time • EBITDA up 8.4% YoY to ₹2,509m, crossing the ₹2,500m mark in a quarter for the first time despite higher input material and freight costs; EBITDA margin at 17.6% • Operational PAT up 11.5% YoY to ₹1,358m; Operational EPS at ₹14.7 • Reported PAT up 2.0% YoY to ₹1,341m; Reported EPS at ₹14.2 Bangalore, India, 29 October 2026 - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q2FY27) and half year (H1FY27) ended 30 September, 2026. Financial Highlights (In ₹m) Particulars (₹m) Q2FY27 Q2FY26 YoY Q1FY27 QoQ H1FY27 H1FY26 YoY Revenue 14,297 12,208 17.1% 12,654 13.0% 26,951 23,406 15.1% Gross Margin 8,003 7,056 13.4% 7,702 3.9% 15,705 13,810 13.7% Gross Margin % 56.0% 57.8% -180 bps 60.9% -490 bps 58.3% 59.0% -70 bps EBITDA 2,509 2,316 8.4% 2,298 9.2% 4,807 4,496 6.9% EBITDA % 17.6% 19.0% -140 bps 18.2% -60 bps 17.8% 19.2% -140 bps Operational PAT 1,358 1,218* 11.5% 1,231 10.3% 2,589 2,358* 9.8% Operational EPS (₹) 14.7 13.2 11.6% 13.4 10.3% 28.1 25.6 9.9% Reported PAT 1,341 1,315 2.0% 1,655 -19.0% 2,996 2,371 26.4% Reported EPS (₹) 14.2 13.8 2.6% 17.0 -16.6% 31.2 24.6 26.7% *Q2FY26 and H1FY26 Operational PAT and Operational EPS exclude one-time finance income of ₹185m; Operational PAT = Reported PAT excluding exceptional items Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides delivered a strong second quarter, with revenue of ₹14,297m growing ~17% YoY, driven by Ex-US Markets. Our diversification strategy continues to play out, with Ex-US Markets growing 31% YoY to ₹6,963m and, for the first time, surpassing our US business in quarterly revenue. Our US business delivered 9% YoY growth. EBITDA grew to ₹2,509m, crossing the ₹2,500m mark in a quarter for the first time. This was despite higher raw material, freight and operating costs arising from geopolitical disruptions. We remain focused on mitigating these pressures through continuous cost optimization initiatives during the year. Net Debt increased by ₹2,114m during H1 due to an elongated cash-to-cash cycle and higher inventory holding to navigate current market conditions. We expect the Net Debt to EBITDA ratio to stabilize by the end of the year. We are also pleased to welcome Mr. Biren Gabhawala to our Board as an Independent Director. His deep expertise in financial reporting, audit and corporate governance will further strengthen the Board’s oversight. While the external environment remains dynamic, we are committed to 1 Strides Pharma Science Ltd. Press Release 29 October 2026 delivering sustainable and profitable growth.” About Strides Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com. For further information, please contact: Investor Relations Corporate Communication Vikesh Kumar: Group CFO Pallavi Panchmatia: +91 80 6784 0193 investor-relations@strides.com Pallavi.panchmatia@strides.com Saurabh Ambaselkar: +91 99609 31220 Abhilash Mukherjee: +91 89044 28907 saurabh.ambaselkar@strides.com Abhilash.Mukherjee@strides.com Adrita Chatterjee: +91 92842 40813 Strides Pharma Science Limited adrita.chatterjee@adfactorspr.com Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076 2 Strides Pharma Science Ltd.